Title: Analysis of Antiviral Efficacy after Switching from Brand to Generic Entecavir in patients
with treatment-naïve chronic hepatitis B
Version: 4 Date: 18 Apr 2022
Reviewer's report:
Dear Authors
“Analysis of Antiviral Efficacy after Switching from Brand to Generic Entecavir in patients with
treatment-naïve chronic hepatitis B”.
This is a study was to evaluate the antiviral activity and safety of ETV-Generic in comparison
to ETV-Brand in patients with CHB. However, this manuscript is still difficult to accept.
1. The reader should read the article that be new or interesting, but there is no new or interesting
content in this manuscript.
2. It cannot be evaluated that there is no difference in effectiveness with only 175 patient data
3. Taiwan is not undeveloped country but developed country.
Title: Analysis of Antiviral Efficacy after Switching from Brand to Generic Entecavir in patients
with treatment-naïve chronic hepatitis B
Version: 4 Date: 18 Apr 2022
Reviewer's report:
Dear Authors
“Analysis of Antiviral Efficacy after Switching from Brand to Generic Entecavir in patients with
treatment-naïve chronic hepatitis B”.
This is a study was to evaluate the antiviral activity and safety of ETV-Generic in comparison
to ETV-Brand in patients with CHB. However, this manuscript is still difficult to accept.
1. The reader should read the article that be new or interesting, but there is no new or interesting
content in this manuscript.
2. It cannot be evaluated that there is no difference in effectiveness with only 175 patient data
3. Taiwan is not undeveloped country but developed country.
Please review this paper.
user
Title: Analysis of Antiviral Efficacy after Switching from Brand to Generic Entecavir in patients
with treatment-naïve chronic hepatitis B
Version: 4 Date: 18 Apr 2022
Reviewer's report:
Dear Authors
“Analysis of Antiviral Efficacy after Switching from Brand to Generic Entecavir in patients with
treatment-naïve chronic hepatitis B”.
This is a study was to evaluate the antiviral activity and safety of ETV-Generic in comparison
to ETV-Brand in patients with CHB. However, this manuscript is still difficult to accept.
1. The reader should read the article that be new or interesting, but there is no new or interesting
content in this manuscript.
2. It cannot be evaluated that there is no difference in effectiveness with only 175 patient data
3. Taiwan is not undeveloped country but developed country.
assistant